[8-K] Kalaris Therapeutics, Inc. Reports Material Event
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Kalaris Therapeutics reported a board change and related director compensation. Morana Jovan-Embiricos, Ph.D., resigned from the board and the Audit Committee, and stated her resignation was not due to any disagreement with the company’s operations, policies or practices.
The board elected Laurie Keating as a Class I director, effective August 1, 2026, with a term running to the 2027 annual meeting. She will also join the Audit Committee. As a non-employee director, she will receive an option for 18,000 shares vesting over three years, annual cash fees for board and committee service, ongoing equity grants under the director compensation policy and standard indemnification protection.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Initial option grant: 18,000 shares
Board cash compensation: $40,000 per year
Audit Committee fee: $7,500 per year
+3 more
6 metrics
Initial option grant
18,000 shares
Stock option to Laurie Keating effective August 1, 2026
Board cash compensation
$40,000 per year
Annual cash fee for Laurie Keating’s board service
Audit Committee fee
$7,500 per year
Additional annual cash compensation for Audit Committee role
Option vesting period
3 years
Option vests in equal monthly installments over three years
Effective date of new director
August 1, 2026
Start date for Laurie Keating’s board and Audit Committee service
Term expiration
2027 annual meeting
End of current term for Class I director seat
Key Terms
Audit Committee, Class I director, non-employee director compensation policy, change in control, +1 more
5 terms
Audit Committee financial
"With the resignation, Dr. Jovan-Embiricos also resigned as a member of the Audit Committee of the Board"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Class I director financial
"Ms. Keating will serve as a Class I director with a term expiring at the 2027 annual meeting"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
non-employee director compensation policy financial
"Ms. Keating will be entitled to compensation for her service as a non-employee director in accordance with the Company’s non-employee director compensation policy"
change in control financial
"In the event of a change in control of the Company, the vesting schedule of the option will accelerate in full"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
indemnification agreement regulatory
"Ms. Keating will enter into the Company’s standard form of indemnification agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
